Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics

Fig. 5

CRISPR-mediated adaptive immunity. Type I-C, type I-E, and type I-F CRISPR-Cas systems have been identified in P. aeruginosa. Type I CRISPR-Cas targeted endogenous LasR gene to decrease TLR4 expression and TLR4-mediated host inflammatory responses. Similarly, type I CRISPR-Cas systems elicited inflammasome activation by promoting mitochondrial-mediated autophagy. Ultimately, CRISPR-mediated adaptive immunity helps P. aeruginosa evade mammalian host immunity

Back to article page